GlassScriptPhysician profile
Laveta L Mcdowell
NPI 1477611176
$4,538.47
in general payments reported to CMS, 2019-2025
31 companies · $878 in 2025
The $878 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $169 · 2021: $704 · 2022: $581 · 2023: $846 · 2024: $950 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,648 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,648.40 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $681.60 | 2019-2025 | Farxiga, Lokelma |
| Daiichi Sankyo INC. | $642.03 | 2019-2025 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $422.42 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $404.72 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $379.96 | 2019-2024 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $248.20 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $231.10 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $198.05 | 2021-2023 | Acthar |
| Cormedix INC. | $142.68 | 2024 | Defencath |
| Akebia Therapeutics INC | $126.43 | 2019-2024 | Vafseo |
| Travere Therapeutics, INC. | $104.23 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $103.86 | 2022-2025 | Tarpeyo |
| Kyowa Kirin, INC. | $100.15 | 2024-2025 | Crysvita |
| Fresenius USA Marketing, INC. | $99.72 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $96.39 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $93.96 | 2023-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $81.80 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $69.91 | 2019 | |
| Glaxosmithkline, LLC. | $41.78 | 2023-2025 | Arexvy, Shingrix, Benlysta |
| Apellis Pharmaceuticals, INC. | $31.17 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.69 | 2024 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.99 | 2023 | Jynarque |
| Genzyme Corporation | $25.98 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $24.01 | 2022 | |
| Pharmacosmos Therapeutics INC. | $22.15 | 2025 | Monoferric |
| Novo Nordisk INC | $21.91 | 2025 | Rybelsus, Ozempic |
| Outset Medical INC | $21.22 | 2023 | |
| Ani Pharmaceuticals, INC. | $19.21 | 2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $16.50 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $16.38 | 2022 | |
| Amicus Therapeutics, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laveta Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.